FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis

R. Fujii, Takanori Kanai, Y. Nemoto, S. Makita, S. Oshima, R. Okamoto, K. Tsuchiya, T. Totsuka, M. Watanabe

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

FTY720, a sphingosine-derived immunomodulator, causes immunosuppression via enhancement of lymphocyte sequestration into secondary lymphoid organs, thereby preventing their antigen-activated T cell egress to sites of inflammation. FTY720 is highly effective in inhibiting autoimmunity in various animal models. However, there is little known about how FTY720 controls the migration property of memory T cells. Here, we demonstrated that FTY720 prevents the development of colitis induced by the adoptive transfer of lamina propria (LP) colitogenic effector memory CD4+ T cells (TEM cells; CD45RB lowCD44highCD62L-) into severe combined immunodeficiency (SCID) mice and suppresses interferon-γ, interleukin-2, and tumor necrosis factor-α production by LP CD4+ T cells. The numbers of spleen, peripheral blood, mesenteric lymph node, and LP CD4 + T cells in FTY720-treated mice were significantly reduced compared with those in control mice. Notably, LP CD4 TEM cells as well as splenic CD4+CD45RBhigh T cells expressed several spingosine-1-phosphate receptors that are targets for FTY720. Furthermore, FTY720 also prevented the development of colitis induced by the adoptive transfer of splenic CD4+CD45RBhigh T cells into SCID mice. Collectively, the present data indicate that FTY720 treatment may offer the potential not only to prevent the onset of disease but also to treat memory T cell-mediated autoimmune diseases including inflammatory bowel diseases.

Original languageEnglish
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume291
Issue number2
DOIs
Publication statusPublished - 2006
Externally publishedYes

Fingerprint

Colitis
T-Lymphocytes
Mucous Membrane
Severe Combined Immunodeficiency
Adoptive Transfer
Sphingosine
Fingolimod Hydrochloride
Immunologic Factors
Autoimmunity
Inflammatory Bowel Diseases
Immunosuppression
Interferons
Autoimmune Diseases
Interleukin-2
Spleen
Animal Models
Tumor Necrosis Factor-alpha
Lymph Nodes
Phosphates
Lymphocytes

Keywords

  • I cell
  • Migration
  • Therapy

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis. / Fujii, R.; Kanai, Takanori; Nemoto, Y.; Makita, S.; Oshima, S.; Okamoto, R.; Tsuchiya, K.; Totsuka, T.; Watanabe, M.

In: American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 291, No. 2, 2006.

Research output: Contribution to journalArticle

Fujii, R. ; Kanai, Takanori ; Nemoto, Y. ; Makita, S. ; Oshima, S. ; Okamoto, R. ; Tsuchiya, K. ; Totsuka, T. ; Watanabe, M. / FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis. In: American Journal of Physiology - Gastrointestinal and Liver Physiology. 2006 ; Vol. 291, No. 2.
@article{fb13fa8d0c5f4c3e90c680191f8e99d1,
title = "FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis",
abstract = "FTY720, a sphingosine-derived immunomodulator, causes immunosuppression via enhancement of lymphocyte sequestration into secondary lymphoid organs, thereby preventing their antigen-activated T cell egress to sites of inflammation. FTY720 is highly effective in inhibiting autoimmunity in various animal models. However, there is little known about how FTY720 controls the migration property of memory T cells. Here, we demonstrated that FTY720 prevents the development of colitis induced by the adoptive transfer of lamina propria (LP) colitogenic effector memory CD4+ T cells (TEM cells; CD45RB lowCD44highCD62L-) into severe combined immunodeficiency (SCID) mice and suppresses interferon-γ, interleukin-2, and tumor necrosis factor-α production by LP CD4+ T cells. The numbers of spleen, peripheral blood, mesenteric lymph node, and LP CD4 + T cells in FTY720-treated mice were significantly reduced compared with those in control mice. Notably, LP CD4 TEM cells as well as splenic CD4+CD45RBhigh T cells expressed several spingosine-1-phosphate receptors that are targets for FTY720. Furthermore, FTY720 also prevented the development of colitis induced by the adoptive transfer of splenic CD4+CD45RBhigh T cells into SCID mice. Collectively, the present data indicate that FTY720 treatment may offer the potential not only to prevent the onset of disease but also to treat memory T cell-mediated autoimmune diseases including inflammatory bowel diseases.",
keywords = "I cell, Migration, Therapy",
author = "R. Fujii and Takanori Kanai and Y. Nemoto and S. Makita and S. Oshima and R. Okamoto and K. Tsuchiya and T. Totsuka and M. Watanabe",
year = "2006",
doi = "10.1152/ajpgi.00496.2005",
language = "English",
volume = "291",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis

AU - Fujii, R.

AU - Kanai, Takanori

AU - Nemoto, Y.

AU - Makita, S.

AU - Oshima, S.

AU - Okamoto, R.

AU - Tsuchiya, K.

AU - Totsuka, T.

AU - Watanabe, M.

PY - 2006

Y1 - 2006

N2 - FTY720, a sphingosine-derived immunomodulator, causes immunosuppression via enhancement of lymphocyte sequestration into secondary lymphoid organs, thereby preventing their antigen-activated T cell egress to sites of inflammation. FTY720 is highly effective in inhibiting autoimmunity in various animal models. However, there is little known about how FTY720 controls the migration property of memory T cells. Here, we demonstrated that FTY720 prevents the development of colitis induced by the adoptive transfer of lamina propria (LP) colitogenic effector memory CD4+ T cells (TEM cells; CD45RB lowCD44highCD62L-) into severe combined immunodeficiency (SCID) mice and suppresses interferon-γ, interleukin-2, and tumor necrosis factor-α production by LP CD4+ T cells. The numbers of spleen, peripheral blood, mesenteric lymph node, and LP CD4 + T cells in FTY720-treated mice were significantly reduced compared with those in control mice. Notably, LP CD4 TEM cells as well as splenic CD4+CD45RBhigh T cells expressed several spingosine-1-phosphate receptors that are targets for FTY720. Furthermore, FTY720 also prevented the development of colitis induced by the adoptive transfer of splenic CD4+CD45RBhigh T cells into SCID mice. Collectively, the present data indicate that FTY720 treatment may offer the potential not only to prevent the onset of disease but also to treat memory T cell-mediated autoimmune diseases including inflammatory bowel diseases.

AB - FTY720, a sphingosine-derived immunomodulator, causes immunosuppression via enhancement of lymphocyte sequestration into secondary lymphoid organs, thereby preventing their antigen-activated T cell egress to sites of inflammation. FTY720 is highly effective in inhibiting autoimmunity in various animal models. However, there is little known about how FTY720 controls the migration property of memory T cells. Here, we demonstrated that FTY720 prevents the development of colitis induced by the adoptive transfer of lamina propria (LP) colitogenic effector memory CD4+ T cells (TEM cells; CD45RB lowCD44highCD62L-) into severe combined immunodeficiency (SCID) mice and suppresses interferon-γ, interleukin-2, and tumor necrosis factor-α production by LP CD4+ T cells. The numbers of spleen, peripheral blood, mesenteric lymph node, and LP CD4 + T cells in FTY720-treated mice were significantly reduced compared with those in control mice. Notably, LP CD4 TEM cells as well as splenic CD4+CD45RBhigh T cells expressed several spingosine-1-phosphate receptors that are targets for FTY720. Furthermore, FTY720 also prevented the development of colitis induced by the adoptive transfer of splenic CD4+CD45RBhigh T cells into SCID mice. Collectively, the present data indicate that FTY720 treatment may offer the potential not only to prevent the onset of disease but also to treat memory T cell-mediated autoimmune diseases including inflammatory bowel diseases.

KW - I cell

KW - Migration

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=33745767310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745767310&partnerID=8YFLogxK

U2 - 10.1152/ajpgi.00496.2005

DO - 10.1152/ajpgi.00496.2005

M3 - Article

VL - 291

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 2

ER -